Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories.

Research output: Contribution to journalArticle

Standard

Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories. / Nishimura, Toshide; Kawamura, Takeshi; Sugihara, Yutaka; Bando, Yasuhiko; Sakamoto, Shigeru; Nomura, Masaharu; Ikeda, Norihiko; Ohira, Tatsuo; Fujimoto, Junichiro; Tojo, Hiromasa; Hamakubo, Takao; Kodama, Tatsuhiko; Andersson, Roland; Fehniger, Thomas E; Kato, Harubumi; Marko-Varga, György.

In: Clinical and Translational Medicine, Vol. 3, No. 1, 61, 2014.

Research output: Contribution to journalArticle

Harvard

Nishimura, T, Kawamura, T, Sugihara, Y, Bando, Y, Sakamoto, S, Nomura, M, Ikeda, N, Ohira, T, Fujimoto, J, Tojo, H, Hamakubo, T, Kodama, T, Andersson, R, Fehniger, TE, Kato, H & Marko-Varga, G 2014, 'Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories.', Clinical and Translational Medicine, vol. 3, no. 1, 61. https://doi.org/10.1186/s40169-014-0038-x

APA

CBE

Nishimura T, Kawamura T, Sugihara Y, Bando Y, Sakamoto S, Nomura M, Ikeda N, Ohira T, Fujimoto J, Tojo H, Hamakubo T, Kodama T, Andersson R, Fehniger TE, Kato H, Marko-Varga G. 2014. Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories. Clinical and Translational Medicine. 3(1). https://doi.org/10.1186/s40169-014-0038-x

MLA

Vancouver

Author

Nishimura, Toshide ; Kawamura, Takeshi ; Sugihara, Yutaka ; Bando, Yasuhiko ; Sakamoto, Shigeru ; Nomura, Masaharu ; Ikeda, Norihiko ; Ohira, Tatsuo ; Fujimoto, Junichiro ; Tojo, Hiromasa ; Hamakubo, Takao ; Kodama, Tatsuhiko ; Andersson, Roland ; Fehniger, Thomas E ; Kato, Harubumi ; Marko-Varga, György. / Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories. In: Clinical and Translational Medicine. 2014 ; Vol. 3, No. 1.

RIS

TY - JOUR

T1 - Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories.

AU - Nishimura, Toshide

AU - Kawamura, Takeshi

AU - Sugihara, Yutaka

AU - Bando, Yasuhiko

AU - Sakamoto, Shigeru

AU - Nomura, Masaharu

AU - Ikeda, Norihiko

AU - Ohira, Tatsuo

AU - Fujimoto, Junichiro

AU - Tojo, Hiromasa

AU - Hamakubo, Takao

AU - Kodama, Tatsuhiko

AU - Andersson, Roland

AU - Fehniger, Thomas E

AU - Kato, Harubumi

AU - Marko-Varga, György

PY - 2014

Y1 - 2014

N2 - The Tokyo Medical University Hospital in Japan and the Lund University hospital in Sweden have recently initiated a research program with the objective to impact on patient treatment by clinical disease stage characterization (phenotyping), utilizing proteomics sequencing platforms. By sharing clinical experiences, patient treatment principles, and biobank strategies, our respective clinical teams in Japan and Sweden will aid in the development of predictive and drug related protein biomarkers. Data from joint lung cancer studies are presented where protein expression from Neuro- Endocrine lung cancer (LCNEC) phenotype patients can be separated from Small cell- (SCLC) and Large Cell lung cancer (LCC) patients by deep sequencing and spectral counting analysis. LCNEC, a subtype of large cell carcinoma (LCC), is characterized by neuroendocrine differentiation that small cell lung carcinoma (SCLC) shares. Pre-therapeutic histological distinction between LCNEC and SCLC has so far been problematic, leading to adverse clinical outcome. An establishment of protein targets characteristic of LCNEC is quite helpful for decision of optimal therapeutic strategy by diagnosing individual patients. Proteoform annotation and clinical biobanking is part of the HUPO initiative (http://www.hupo.org) within chromosome 10 and chromosome 19 consortia.

AB - The Tokyo Medical University Hospital in Japan and the Lund University hospital in Sweden have recently initiated a research program with the objective to impact on patient treatment by clinical disease stage characterization (phenotyping), utilizing proteomics sequencing platforms. By sharing clinical experiences, patient treatment principles, and biobank strategies, our respective clinical teams in Japan and Sweden will aid in the development of predictive and drug related protein biomarkers. Data from joint lung cancer studies are presented where protein expression from Neuro- Endocrine lung cancer (LCNEC) phenotype patients can be separated from Small cell- (SCLC) and Large Cell lung cancer (LCC) patients by deep sequencing and spectral counting analysis. LCNEC, a subtype of large cell carcinoma (LCC), is characterized by neuroendocrine differentiation that small cell lung carcinoma (SCLC) shares. Pre-therapeutic histological distinction between LCNEC and SCLC has so far been problematic, leading to adverse clinical outcome. An establishment of protein targets characteristic of LCNEC is quite helpful for decision of optimal therapeutic strategy by diagnosing individual patients. Proteoform annotation and clinical biobanking is part of the HUPO initiative (http://www.hupo.org) within chromosome 10 and chromosome 19 consortia.

U2 - 10.1186/s40169-014-0038-x

DO - 10.1186/s40169-014-0038-x

M3 - Article

VL - 3

JO - Clinical and Translational Medicine

JF - Clinical and Translational Medicine

SN - 2001-1326

IS - 1

M1 - 61

ER -